We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Warns of Lower Survival Rates for Certain Patients in Keytruda, Tecentriq Monotherapy Trials
FDA Warns of Lower Survival Rates for Certain Patients in Keytruda, Tecentriq Monotherapy Trials
The FDA issued an alert to clinical investigators, doctors and consumers about safety issues associated with use of Keytruda or Tecentriq as a monotherapy in oncology clinical trials.